The required information typically includes: Diagnosis: Documentation of the patients condition, such as type 2 diabetes, obesity, hypertension, or cardiovascular issues, that warrants the use of a GLP-1 medication
Avoid lying down immediately after eating, and try to identify specific trigger foods that worsen your symptoms
Taken together, these findings should be interpreted cautiously, as most available data derive from small studies or indirect evidence and may not be directly generalizable to early PsA populations
Previously, administration of GC via oral, rectal, IV and IM routes was prohibited in-competition due to clear evidence of systemic effects however this ban has now been extended to include any in-competition injection of GC (e.g., intravenous, intramuscular, periarticular, intra-articular, peritendinous, intratendinous, epidural, intrathecal, intrabursal, intralesional (e.g., intrakeloid), intradermal, and subcutaneous)
